Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)

Summary

The purpose of this trial is to evaluate the efficacy and safety of tralokinumab administered as subcutaneous (SC) injection by an autoinjector in adults and adolescents (age 12 to 17 years) with moderate-to-severe atopic dermatitis (AD).

Timeline

Start

2022-01-13

Primary completion

2023-06-06

Completion

2023-06-21

Publications

• Soung J, Laquer V, Zirwas M, van Iperen P, Stinson JC, Albertsen KL, Stein Gold L. The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA). Dermatol Ther (Heidelb). 2025 Sep;15(9):2631-2644. doi: 10.1007/s13555-025-01490-3. Epub 2025 Jul 18.

Drugs

Indications